Related Experiment Videos
Cholesterol microembolization and stable renal function with continued anticoagulation
1Department of Internal Medicine, Eisenhower Army Medical Center, Fort Gordon, Ga.
Insights
Cholesterol microembolization, a complication of oral anticoagulants, can cause organ infarction. However, high-dose heparin therapy stabilized renal function in a patient with purple toes syndrome, suggesting a potential treatment alternative.
Area of Science:
- Cardiovascular Medicine
- Nephrology
- Pharmacology
Background:
- Cholesterol microembolization is a serious complication of oral anticoagulant therapy.
- It can lead to infarction in multiple organs and has a high mortality rate.
- Discontinuing anticoagulation was the standard approach to slow disease progression.
Observation:
- A patient with a prosthetic heart valve developed purple toes syndrome.
- This syndrome is a known manifestation of cholesterol microembolization.
- The patient's renal function was monitored closely.
Findings:
- Initiation of high-dose subcutaneous heparin therapy was administered.
- Stable renal function was observed following heparin treatment.
- This suggests heparin may halt or reverse microembolic progression.
Implications:
- High-dose heparin may be a viable alternative treatment for cholesterol microembolization.
- This approach could potentially prevent further organ damage in affected patients.
- Further research is warranted to confirm the efficacy and safety of heparin in this context.
Abstract:
Cholesterol microembolization as a sequela of oral anticoagulant therapy has been reported to cause infarction of virtually any organ, often resulting in death. Until recently, discontinuance of anticoagulant therapy has been recommended, as this cessation has been shown to slow or halt further tissue infarction. I have described a patient with a prosthetic heart valve in whom the purple toes syndrome developed. Stable renal function followed the initiation of high-dose subcutaneous heparin therapy.